Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11040032 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US9867815 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10016407 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10413505 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10933060 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10987347 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10973811 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10420760 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10894012 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10149843 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10231961 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) | |
US10857095 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 14 December, 2021
Market Authorisation Date: 14 December, 2017
Treatment: Method of administering a local anesthetic to the mucous membranes in geriatric patients; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject...
Dosage: SOLUTION;NASAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10231931 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(13 years from now) | |
US10406108 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(13 years from now) |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 06 June, 2003
Treatment: NA
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9364439 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 10 months ago) | |
US6926907 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(1 year, 1 month ago) | |
US8206741 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(1 year, 1 month ago) | |
US9987231 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Jan, 2033
(8 years from now) | |
US9539214 | GENUS LIFESCIENCES | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
Mar, 2033
(8 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Combination(NC) | Sep 14, 2019 |
Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient
Market Authorisation Date: 14 September, 2016
Treatment: Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers; For secondary prevention of cardi...
Dosage: TABLET, DELAYED RELEASE;ORAL